A sto­ried Chi­nese phar­ma part­ner of Bris­tol My­ers, Am­gen — and avid biotech sup­port­er — plots HK IPO

A hefty phar­ma IPO is com­ing to Hong Kong.

Sim­cere isn’t one of the group of pre-rev­enue biotechs tak­ing ad­van­tage of Hong Kong’s 2-year-old new rules that opened up the stock ex­change. A clos­er coun­ter­part would be Han­soh, which reaped a $1 bil­lion wind­fall from its HKEX de­but a year ago: a sto­ried pow­er­house com­pa­ny that bags siz­able rev­enue from a slate of old­er gener­ic drugs. (Co­in­ci­den­tal­ly, both com­pa­nies have head­quar­ters in the province of Jiang­su.)

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN